369 related articles for article (PubMed ID: 31124078)
1. Palbociclib Effectively Halts Proliferation but Fails to Induce Senescence in Patient-Derived Glioma Stem Cells.
Morris-Hanon O; Marazita MC; Romorini L; Isaja L; Fernandez-Espinosa DD; Sevlever GE; Scassa ME; Videla-Richardson GA
Mol Neurobiol; 2019 Nov; 56(11):7810-7821. PubMed ID: 31124078
[TBL] [Abstract][Full Text] [Related]
2. Anti-cell growth and anti-cancer stem cell activity of the CDK4/6 inhibitor palbociclib in breast cancer cells.
Kishino E; Ogata R; Saitoh W; Koike Y; Ohta Y; Kanomata N; Kurebayashi J
Breast Cancer; 2020 May; 27(3):415-425. PubMed ID: 31823286
[TBL] [Abstract][Full Text] [Related]
3. Sustained mTORC1 activity during palbociclib-induced growth arrest triggers senescence in ER+ breast cancer cells.
Maskey RS; Wang F; Lehman E; Wang Y; Emmanuel N; Zhong W; Jin G; Abraham RT; Arndt KT; Myers JS; Mazurek A
Cell Cycle; 2021 Jan; 20(1):65-80. PubMed ID: 33356791
[TBL] [Abstract][Full Text] [Related]
4. Targeting cancer stem cell propagation with palbociclib, a CDK4/6 inhibitor: Telomerase drives tumor cell heterogeneity.
Bonuccelli G; Peiris-Pages M; Ozsvari B; Martinez-Outschoorn UE; Sotgia F; Lisanti MP
Oncotarget; 2017 Feb; 8(6):9868-9884. PubMed ID: 28039467
[TBL] [Abstract][Full Text] [Related]
5. Evidence for a CDK4-dependent checkpoint in a conditional model of cellular senescence.
Brookes S; Gagrica S; Sanij E; Rowe J; Gregory FJ; Hara E; Peters G
Cell Cycle; 2015; 14(8):1164-73. PubMed ID: 25695870
[TBL] [Abstract][Full Text] [Related]
6. Palbociclib-induced autophagy and senescence in gastric cancer cells.
Valenzuela CA; Vargas L; Martinez V; Bravo S; Brown NE
Exp Cell Res; 2017 Nov; 360(2):390-396. PubMed ID: 28947133
[TBL] [Abstract][Full Text] [Related]
7. Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6.
Yoshida A; Lee EK; Diehl JA
Cancer Res; 2016 May; 76(10):2990-3002. PubMed ID: 26988987
[TBL] [Abstract][Full Text] [Related]
8. Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells.
Bonelli MA; Digiacomo G; Fumarola C; Alfieri R; Quaini F; Falco A; Madeddu D; La Monica S; Cretella D; Ravelli A; Ulivi P; Tebaldi M; Calistri D; Delmonte A; Ampollini L; Carbognani P; Tiseo M; Cavazzoni A; Petronini PG
Neoplasia; 2017 Aug; 19(8):637-648. PubMed ID: 28704762
[TBL] [Abstract][Full Text] [Related]
9. Progress of CDK4/6 Inhibitor Palbociclib in the Treatment of Cancer.
Chen F; Liu C; Zhang J; Xu W; Zhang Y
Anticancer Agents Med Chem; 2018; 18(9):1241-1251. PubMed ID: 28403773
[TBL] [Abstract][Full Text] [Related]
10. Potent anti-tumor efficacy of palbociclib in treatment-naïve H3.3K27M-mutant diffuse intrinsic pontine glioma.
Sun Y; Sun Y; Yan K; Li Z; Xu C; Geng Y; Pan C; Chen X; Zhang L; Xi Q
EBioMedicine; 2019 May; 43():171-179. PubMed ID: 31060906
[TBL] [Abstract][Full Text] [Related]
11. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.
Knudsen ES; Hutcheson J; Vail P; Witkiewicz AK
Oncotarget; 2017 Jul; 8(27):43678-43691. PubMed ID: 28620137
[TBL] [Abstract][Full Text] [Related]
12. FGFR1 Overexpression Induces Cancer Cell Stemness and Enhanced Akt/Erk-ER Signaling to Promote Palbociclib Resistance in Luminal A Breast Cancer Cells.
Cheng Q; Ma Z; Shi Y; Parris AB; Kong L; Yang X
Cells; 2021 Nov; 10(11):. PubMed ID: 34831231
[TBL] [Abstract][Full Text] [Related]
13. Cyclin E overexpression confers resistance to the CDK4/6 specific inhibitor palbociclib in gastric cancer cells.
Min A; Kim JE; Kim YJ; Lim JM; Kim S; Kim JW; Lee KH; Kim TY; Oh DY; Bang YJ; Im SA
Cancer Lett; 2018 Aug; 430():123-132. PubMed ID: 29729292
[TBL] [Abstract][Full Text] [Related]
14. Stromal Senescence By Prolonged CDK4/6 Inhibition Potentiates Tumor Growth.
Guan X; LaPak KM; Hennessey RC; Yu CY; Shakya R; Zhang J; Burd CE
Mol Cancer Res; 2017 Mar; 15(3):237-249. PubMed ID: 28039358
[TBL] [Abstract][Full Text] [Related]
15. Thermal proteome profiling of breast cancer cells reveals proteasomal activation by CDK4/6 inhibitor palbociclib.
Miettinen TP; Peltier J; Härtlova A; Gierliński M; Jansen VM; Trost M; Björklund M
EMBO J; 2018 May; 37(10):. PubMed ID: 29669860
[TBL] [Abstract][Full Text] [Related]
16. Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation.
Bonelli M; La Monica S; Fumarola C; Alfieri R
Biochem Pharmacol; 2019 Dec; 170():113676. PubMed ID: 31647925
[TBL] [Abstract][Full Text] [Related]
17. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
Raub TJ; Wishart GN; Kulanthaivel P; Staton BA; Ajamie RT; Sawada GA; Gelbert LM; Shannon HE; Sanchez-Martinez C; De Dios A
Drug Metab Dispos; 2015 Sep; 43(9):1360-71. PubMed ID: 26149830
[TBL] [Abstract][Full Text] [Related]
18. PD-0332991, a CDK4/6 inhibitor, significantly prolongs survival in a genetically engineered mouse model of brainstem glioma.
Barton KL; Misuraca K; Cordero F; Dobrikova E; Min HD; Gromeier M; Kirsch DG; Becher OJ
PLoS One; 2013; 8(10):e77639. PubMed ID: 24098593
[TBL] [Abstract][Full Text] [Related]
19. A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitors.
Menon M; Elliott R; Bowers L; Balan N; Rafiq R; Costa-Cabral S; Munkonge F; Trinidade I; Porter R; Campbell AD; Johnson ER; Esdar C; Buchstaller HP; Leuthner B; Rohdich F; Schneider R; Sansom O; Wienke D; Ashworth A; Lord CJ
Sci Rep; 2019 Jan; 9(1):201. PubMed ID: 30655555
[TBL] [Abstract][Full Text] [Related]
20. CDK4/6 inhibitor palbociclib enhances the effect of pyrotinib in HER2-positive breast cancer.
Zhang K; Hong R; Kaping L; Xu F; Xia W; Qin G; Zheng Q; Lu Q; Zhai Q; Shi Y; Yuan Z; Deng W; Chen M; Wang S
Cancer Lett; 2019 Apr; 447():130-140. PubMed ID: 30677445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
